Davis Polk & Wardwell and Zhong Lun Law Firm advised Chinese biopharmaceutical company Antengene Corporation on its $335 million IPO in Hong Kong, with Herbert Smith Freehills and Commerce & Finance Law Offices advising the joint sponsors and the underwriters.

Antengene is a clinical-stage Asia-Pacific biopharmaceutical company offering R&D capabilities and oncology therapies.

The listing is the latest by a Chinese biopharmaceutical company in Hong Kong, which has seen a flurry of such IPOs. Recent other issuers include Simcere Pharmaceutical Group, JHBP (CY) Holdings and Everest Medicines.

The Herbert Smith Freehills team was led by Matt Emsley and Stanley Xie.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Features

BRIEF: Malaysia Offers Investors Cooling IPO Respite During Sluggish Summer

by Sarah Wong |

In a year when global IPO markets have wilted under the economic heat, Bursa Malaysia has stood out as a surprising oasis of activity.

Deals

JSA, Trilegal act on NTPC Green’s upcoming $1.2bln IPO

by Nimitt Dixit |

JSA Advocates & Solicitors is advising NTPC Green Energy, state-run power producer National Thermal Power Corporation’s renewable energy arm, on its announced initial public offering worth $1.2 billion, with Trilegal advising the book running lead managers.

Deals

CAM, Khaitan, Links act on Bajaj Housing Finance’s $782mln IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Indian home-loan financier Bajaj Housing Finance (BHF) and its promoter Bajaj Finance on BHF’s $782 million initial public offering, with Khaitan & Co and Linklaters representing the book-running lead managers to the offer.